Tolbutamide

Tolbutamide is an orally active KATP inhibitor. Tolbutamide inhibits cell proliferation, stimulates exocytosis of glucagon and reduces fetal lethality of mice. Tolbutamide can be used in the research of diabete[1][2][3][4].

Product Specifications

CAS Number

[64-77-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Na+/K+ ATPase

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Cancer-Kinase/protease

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Tolbutamide.html

Purity

99.96

Solubility

DMSO : ≥ 34 mg/mL

Smiles

O=S(C1=CC=C(C)C=C1)(NC(NCCCC)=O)=O

Molecular Formula

C12H18N2O3S

Molecular Weight

270.35

Precautions

H302, H315, H319, H335

References & Citations

[1]Sánchez‐Alvarez R, et al. Tolbutamide reduces glioma cell proliferation by increasing connexin43, which promotes the up‐regulation of p21 and p27 and subsequent changes in retinoblastoma phosphorylation [J]. Glia, 2006, 54 (2) : 125-134.|[2]Hœy M, et al. Tolbutamide stimulates exocytosis of glucagon by inhibition of a mitochondrial‐like ATP‐sensitive K+ (KATP) conductance in rat pancreatic A‐cells [J]. The Journal of Physiology, 2000, 527 (1) : 109-120.|[3]Williams A J K, et al. Tolbutamide reduces the incidence of diabetes mellitus, but not insulitis, in the non-obese-diabetic mouse [J]. Diabetologia, 1993, 36: 487-492.|[4]Belisle R J, et al. Tolbutamide treatment of pregnant mice: repeated administration reduces fetal lethality [J]. Teratology, 1976, 13 (1) : 65-70.